Melco Resorts & Entertainment Valuation
Is 0A2P undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0A2P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0A2P ($6) is trading below our estimate of fair value ($10.93)
Significantly Below Fair Value: 0A2P is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0A2P?
Key metric: As 0A2P is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0A2P's PS Ratio? | |
|---|---|
| PS Ratio | 0.6x |
| Sales | US$4.54b |
| Market Cap | US$2.57b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 8.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0A2P's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.8x | ||
PTEC Playtech | 1.5x | 3.1% | UK£2.2b |
ENT Entain | 1x | 4.5% | UK£4.8b |
RNK Rank Group | 0.6x | 5.8% | UK£416.9m |
EVOK Evoke | 0.1x | 5.9% | UK£241.4m |
0A2P Melco Resorts & Entertainment | 0.6x | 7.1% | US$2.6b |
Price-To-Sales vs Peers: 0A2P is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (0.8x).
Price to Sales Ratio vs Industry
How does 0A2P's PS Ratio compare vs other companies in the GB Hospitality Industry?
Price-To-Sales vs Industry: 0A2P is good value based on its Price-To-Sales Ratio (0.6x) compared to the UK Hospitality industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is 0A2P's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.6x |
| Fair PS Ratio | 1.5x |
Price-To-Sales vs Fair Ratio: 0A2P is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$6.00 | US$9.50 +58.3% | 13.6% | US$11.50 | US$7.00 | n/a | 14 |
| Nov ’25 | US$6.70 | US$9.39 +40.2% | 15.0% | US$11.50 | US$6.00 | n/a | 14 |
| Oct ’25 | US$8.04 | US$9.02 +12.2% | 19.4% | US$11.50 | US$6.00 | n/a | 14 |
| Sep ’25 | US$5.06 | US$9.29 +83.7% | 21.3% | US$14.00 | US$6.00 | n/a | 14 |
| Aug ’25 | US$5.19 | US$10.21 +96.9% | 19.3% | US$14.00 | US$7.00 | n/a | 14 |
| Jul ’25 | US$6.99 | US$10.69 +53.1% | 14.6% | US$14.00 | US$7.60 | n/a | 14 |
| Jun ’25 | US$7.89 | US$10.51 +33.3% | 15.2% | US$14.00 | US$7.60 | n/a | 14 |
| May ’25 | US$6.58 | US$10.21 +55.4% | 18.0% | US$14.00 | US$7.50 | n/a | 14 |
| Apr ’25 | US$7.23 | US$11.30 +56.2% | 19.3% | US$15.00 | US$8.30 | n/a | 13 |
| Mar ’25 | US$7.06 | US$11.52 +63.3% | 16.7% | US$15.00 | US$9.20 | n/a | 13 |
| Feb ’25 | US$8.15 | US$11.87 +45.7% | 15.7% | US$15.00 | US$8.60 | n/a | 13 |
| Jan ’25 | US$8.94 | US$12.21 +36.6% | 14.5% | US$15.00 | US$8.60 | n/a | 13 |
| Dec ’24 | US$7.00 | US$12.95 +85.2% | 19.6% | US$17.70 | US$8.60 | n/a | 11 |
| Nov ’24 | US$7.99 | US$16.41 +105.5% | 14.5% | US$20.00 | US$13.10 | US$6.70 | 11 |
| Oct ’24 | US$9.78 | US$16.40 +67.8% | 18.4% | US$20.00 | US$9.70 | US$8.04 | 12 |
| Sep ’24 | US$11.13 | US$16.54 +48.6% | 17.7% | US$20.00 | US$9.70 | US$5.06 | 13 |
| Aug ’24 | US$13.25 | US$16.50 +24.6% | 17.1% | US$19.90 | US$9.70 | US$5.19 | 13 |
| Jul ’24 | US$12.09 | US$16.26 +34.5% | 17.4% | US$19.50 | US$9.70 | US$6.99 | 12 |
| Jun ’24 | US$10.86 | US$16.03 +47.6% | 17.6% | US$19.80 | US$9.70 | US$7.89 | 13 |
| May ’24 | US$13.53 | US$15.10 +11.6% | 27.2% | US$19.80 | US$4.60 | US$6.58 | 13 |
| Apr ’24 | US$12.77 | US$14.79 +15.9% | 27.4% | US$19.60 | US$4.60 | US$7.23 | 13 |
| Mar ’24 | US$13.60 | US$14.04 +3.2% | 32.1% | US$19.80 | US$4.60 | US$7.06 | 14 |
| Feb ’24 | US$13.60 | US$13.31 -2.1% | 31.7% | US$19.80 | US$4.60 | US$8.15 | 14 |
| Jan ’24 | US$11.41 | US$10.01 -12.3% | 31.8% | US$14.00 | US$4.60 | US$8.94 | 14 |
| Dec ’23 | US$8.67 | US$9.29 +7.2% | 30.0% | US$13.70 | US$4.60 | US$7.00 | 14 |
| Nov ’23 | US$5.76 | US$8.86 +53.9% | 34.3% | US$13.30 | US$4.60 | US$7.99 | 14 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.